Fenofibrate mitigates microglial activation by reprogramming lipid metabolism and inhibiting ferroptosis

Ahmet Taskesen1, Ceyhan Hacioglu2, Sibel Tuncer3

  • 1Faculty of Medicine, Department of Neurosurgery, Düzce University, Düzce, Turkey.

Insights

Fenofibrate reduces inflammation and oxidative stress in activated microglia by modulating lipid metabolism and inhibiting ferroptosis. This drug may offer protective effects against neuroinflammation and neurodegeneration by rebalancing cellular processes.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pharmacology

Background:

  • Microglial activation is key in neuroinflammation and neurodegeneration.
  • Dysregulated lipid metabolism and ferroptosis contribute to microglial dysfunction.
  • Targeted pharmacological interventions for these pathways are limited.

Purpose of the Study:

  • To investigate fenofibrate's effects on lipid metabolism, oxidative stress, and ferroptosis in activated human microglia.
  • To explore fenofibrate's potential as a therapeutic agent for microglial dysfunction.

Main Methods:

  • Human HMC3 microglia were activated with lipopolysaccharide (LPS) and interferon-γ (IFN-γ) and pre-treated with fenofibrate.
  • Assessed cell viability, cytokine release (TNF-α, IL-1β, IL-6), oxidative stress markers (ROS, MDA, GSH), lipid droplet accumulation, and ferroptosis markers (Fe²⁺, ACSL4, GPX4).
  • Utilized ELISA, fluorescence imaging, qRT-PCR, and Western blotting for analysis.

Main Results:

  • Fenofibrate reduced pro-inflammatory cytokines, restored mitochondrial potential, and decreased oxidative stress (ROS, MDA) while increasing glutathione (GSH).
  • It lowered lipid droplet accumulation by downregulating PLIN2, DGAT1, and GPAT4, enhancing fatty acid oxidation and lipolysis.
  • Fenofibrate attenuated ferroptosis by reducing Fe²⁺ and ACSL4 expression and increasing GPX4, improving cell survival.

Conclusions:

  • Fenofibrate modulates lipid metabolism and suppresses ferroptosis in activated microglia.
  • It improves metabolic and redox balance, suggesting potential protective effects in neuroinflammatory conditions.
  • Fenofibrate shows promise for targeting microglial dysfunction in neurodegenerative diseases.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Necrosis01:16

Necrosis

Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
5.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
120